ArticlemedRxiv : the preprint server for health sciences2026
Automated Phenotyping of Mitral Stenosis Using Deep Learning.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background and Aims: Accurate classification of mitral stenosis (MS) remains a significant clinical challenge. This study aimed to develop an artificial intelligence (AI) framework to automatically detect clinically significant MS from echocardiography. Methods: We developed EchoNet-MS, an open-source end-to-end integrated approach combining video based convolutional neural networks to assess MS severity and differentiate rheumatic etiology from echocardiography and validated its performance across four cohorts. Results: EchoNet-MS was trained and validated in total of 431,612 videos from 44,671 studies from three different healthcare system. Combining assessments from multiple echocardiographic videos, the model was trained on a Kaiser Permanente Northern California (KPNC) cohort of 8,677 studies from 7,576 patients with a range of MS severity. The model was validated on a KPNC held-out test cohort (N=1,623) and a temporally distinct cohort (N=19,206), as well as Stanford Healthcare (SHC) cohort (N=3,333) and Cedars-Sinai Medical Center (CSMC) cohort (N=72,909). EchoNet-MS achieved excellent discrimination of severe MS with AUC 0.937 [95% CI: 0.913 - 0.958] in the KPNC held-out cohort, 0.994 [0.986 - 0.999] in the temporally distinct cohort, 0.991 [0.986 - 0.995] in SHC, and 0.973 [0.958 - 0.987] in CSMC. The model achieved excellent performance in classifying both rheumatic or non-rheumatic MS with AUC ranging from 0.890 and 0.967. Conclusions: EchoNet-MS accurately assesses MS severity and etiology using information from multiple echocardiographic views. Its strong performance generalizes robustly to external cohorts and shows potential as an automated clinical decision support tool.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.